Completed enrolment of first cohort of phase I trial FMPV-1-01 in healthy volunteers

It is announced that all eight subjects of the first cohort of our phase I study FMPV-1-01 in healthy volunteers now are enrolled. All eight subjects have received their first dose of FMPV-1 co-administered with adjuvant GM-CSF without observation of related adverse reactions.

The phase I study will assess safety and immune response in up to 16 subjects. In a first cohort eight subjects will be enrolled and, depending on the results, a second cohort of another eight subjects given a higher dose of FMPV-1 will follow. It is aimed at completing enrolment and active treatment in the study within the next six months.

This website uses cookies to ensure you get the best experience on our website.